FDA lifts full clinical hold on Inhibikase's IkT-148009 for Parkinson's; Phase 2a trial restarting

Inhibikase Therapeutics, Inc.

FDA lifted full clinical hold on IkT-148009; Phase 2a 201 trial resumes at 50 and 100 mg doses.
Company will measure safety and steady-state PK of 200 mg in 6 healthy subjects before PD patient dosing.
Expanded ocular monitoring includes cornea/lens; no ocular pathology observed to date.
Inhibikase intends to seek lift of clinical hold on its Multiple System Atrophy (MSA) program.
Publication in Science Translational Medicine shows IkT-148009 halts neurodegeneration and reduces alpha-synuclein pathology in mouse models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.